Rodent chemotherapy-induced peripheral neuropathy (CIPN) model

You are here: Home » Products » Rodent chemotherapy-induced peripheral neuropathy (CIPN) model

Rodent chemotherapy-induced peripheral neuropathy (CIPN) model

Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-limiting side effect of many anticancer drugs that affects sensory and motor nerve fibers, causing paresthesia, numbness, balance problems, pain, and muscle weakness. Platinum-based chemotherapy drugs such as cisplatin have molecular affinity for the peripheral nervous system, which lacks vascular barriers, resulting in severe peripheral neurotoxicity in most treated cancer patients. HKeyBio offers well-validated cisplatin-induced CIPN models in two species: SD rats and C57BL/6 mice. These models recapitulate key features of human CIPN, including changes in body weight, reduced pain threshold (mechanical allodynia as measured by von Frey), and sensory impairment. They provide a powerful platform for preclinical efficacy testing of novel neuroprotective and analgesic agents for CIPN prevention and treatment.

Quantity:
Availability:





Inquire Add to Basket

Product Description

Main features and benefits

Clinical relevance —Cisplatin-induced neuropathy is similar to human CIPN, with sensory deficits, pain, and weight changes.

Quantifiable endpoint translational value for multiple species IND-ready data package - can be studied according to GLP principles .

Technical data and verification

Cisplatin-induced SD CIPN model

Cisplatin-induced C57BL/6 CIPN model

Application areas

• Efficacy testing of neuroprotective agents (acetyl-L-carnitine, vitamin E, glutathione, amifostine)

• Evaluation of analgesic drugs (gabapentin, pregabalin, duloxetine, tricyclic antidepressants) for the treatment of neuropathic pain

• Targeted validation of neuropathic pain pathways and nerve regeneration strategies

• Biomarker discovery (neurofilament light chain, inflammatory mediators)

• Pharmacology and toxicology studies to support IND

Model specifications

scope	Rat CIPN model	Mouse CIPN model
Species/Strain	Sprague-Dawley Rat	C57BL/6 mouse
induction method	Cisplatin ip 2–4 mg/kg 2–3 times weekly for 2–5 weeks	Cisplatin ip 2–3 mg/kg 2–3 times weekly for 2–4 weeks
study time	3–6 weeks (induction + treatment)	3-5 weeks (induction + treatment)
critical endpoint	Body weight, mechanical withdrawal threshold (von Frey), optional: thermal sensitivity (hot plate, Hargreaves), nerve conduction velocity, histopathology (neuromorphology), intraepidermal nerve fiber density
packet	Raw data, analysis report, behavioral data, histology slides (optional), bioinformatics (optional)

❓ FAQ

Q: How does cisplatin induce peripheral neuropathy?

Answer: Cisplatin accumulates in the peripheral nervous system that lacks vascular barriers, causing DNA cross-linking, mitochondrial dysfunction, oxidative stress, and axonal degeneration of sensory neurons, leading to neuropathic pain and sensory deficits.

Q: What are the main similarities to human CIPN?

A: These models exhibit progressive mechanical allodynia, weight loss, and sensory deficits that closely mirror human CIPN symptoms such as numbness, tingling, and pain in the extremities.

Q: Can these models be used for IND support studies?

Answer: Yes. Studies can be conducted according to GLP principles for regulatory submissions (FDA, EMA).

Q: Do you offer customized study protocols (e.g., different cisplatin doses, treatment regimens, combinations with other chemotherapy)?

Answer: Of course. Our scientific team customizes cisplatin dosing regimens, dosing schedules, and endpoint analyzes based on your specific drug candidate.